一种粪肠球菌及其在治疗或缓解高尿酸血症中的应用
By using a bacterial agent prepared from Enterococcus faecalis CML390 strain, the problems of side effects and dysbiosis in the treatment of hyperuricemia have been solved. This approach achieves the effect of reducing serum uric acid, creatinine, and urea nitrogen levels without side effects, and alleviating liver and kidney damage, thus providing a novel treatment option for hyperuricemia.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHINA AGRI UNIV
- Filing Date
- 2023-02-16
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for hyperuricemia have side effects and cause gut microbiota dysbiosis, and current methods are not very effective in reducing serum uric acid, creatinine, and blood urea nitrogen levels, or in alleviating liver and kidney damage.
Using Enterococcus faecalis CML390 strain, bacterial agents containing Enterococcus faecalis or its metabolites are obtained through cultivation under specific conditions. Combined with carrier materials, these agents are prepared into various dosage forms for the production of products that reduce serum uric acid, creatinine, and urea nitrogen levels, and alleviate liver and kidney damage.
Enterococcus faecalis CML390 significantly reduces serum uric acid, creatinine, and blood urea nitrogen levels in mice, alleviates liver and kidney damage, and provides a novel probiotic solution for the treatment of hyperuricemia without side effects.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3